Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding disorders related to factor VIII deficiency.

• Treatment of acute bleeding episodes in patients with hemophilia A.
• Routine prophylaxis to prevent spontaneous bleeds in hemophilia A.
• Management of bleeding and surgical prophylaxis in von Willebrand disease of any type.
• Replacement therapy during major surgery or invasive procedures in patients lacking factor VIII or von Willebrand factor.
• Supportive therapy in patients with combined factor VIII and von Willebrand factor deficiency.

Adverse reactions reported with Haemate P vary in frequency and severity.

Common

• Headache, fever, chills, or infusion‑related reactions such as erythema at the site.
• Nausea, vomiting, or abdominal discomfort.
• Transient elevations in liver enzymes.
• Mild allergic symptoms like rash or itching.

Serious

• Development of inhibitors (antibodies) against factor VIII, reducing efficacy.
• Severe allergic reactions including anaphylaxis.
• Thrombotic events such as deep vein thrombosis.
• Renal impairment or hemolysis in rare cases.

Clinicians should consider several precautions when prescribing Haemate P to ensure safe use.

• Screen for pre‑existing factor VIII inhibitors before initiating therapy.
• Monitor inhibitor titres regularly during long‑term treatment.
• Use caution in patients with a history of allergic reactions to plasma‑derived products.
• Adjust dose in individuals with renal or hepatic impairment.
• Avoid rapid infusion rates to reduce risk of infusion‑related reactions.
• Observe for signs of thrombosis, especially in patients receiving concurrent pro‑coagulant agents.

Haemate P may interact with other medications that affect coagulation or immune response.

Avoid

• Concomitant use of other factor concentrates without medical supervision.
• High‑dose aspirin or non‑steroidal anti‑inflammatory drugs that increase bleeding risk.

Use with caution

• Immunosuppressive agents that may alter inhibitor development.
• Antifibrinolytic agents (e.g., tranexamic acid) when used together, requiring dose adjustment.
• Other intravenous products administered through the same line without proper flushing.